If most injections are also ~30 days after manufacture, product expiration would be redundant in terms of the resulting AE plot and real world impact. So we would need the injections by date after manufacture plot to see if there are any people actually being protected by hypothetical product expiry.
If most injections are also ~30 days after manufacture, product expiration would be redundant in terms of the resulting AE plot and real world impact. So we would need the injections by date after manufacture plot to see if there are any people actually being protected by hypothetical product expiry.
On the other hand if manufacturer, cold chain, and dosage inconsistency determine functioning mRNA payload, it’s pure Russian Roulette. I think Bhargava recently mentioned LNP bubble size as a potential payload randomizer. But VAERS is full of dilution/injection errors, including for the 5-11 product.
But the Röltgen, K. et al. paper suggests consistent payload at least in the sense that no one is getting “no spike.” 96% of recipients have detectable spike in plasma on day 1-2 and 63% at day 7. Similar results for mRNA and spike in the germ centers, with lots of hits still on day 37 post 2nd-dose and few after. So it seems like everyone who gets the shot is getting a lot of intact mRNA. The variability is in how long it sticks around.
Not discussed much, the paper also finds aberrantly cross-protective antibody enrichment against the RBD vs non-mRNA shots or infection with “Wuhan” strain (fig 4), as in binding against variants / binding against Wuhan ratio was much more even for Pfizer recipients. Even though the mRNA supposedly codes for the Wuhan spike. This suggests there is variability in the output, perhaps lots of mutant spike production, though it could also be some weird influence on APC epitope selection, maybe from the pseudouridine, maybe from the “slow release” factor of mRNA continuing to become available to APCs for weeks after dosage. Malone says the results suggest the mRNA is lingering in the immune cells but I think it reflects delayed capture from transfected non-immune cells.
Perhaps someone should have tested how these things work in a lab or something.
Interesting. I found my notes and it was Bhargava, but it was in a video so there were no citations. Superfluous anyway, if the mRNA payload is randomized or placebo'ed by other means.
If most injections are also ~30 days after manufacture, product expiration would be redundant in terms of the resulting AE plot and real world impact. So we would need the injections by date after manufacture plot to see if there are any people actually being protected by hypothetical product expiry.
On the other hand if manufacturer, cold chain, and dosage inconsistency determine functioning mRNA payload, it’s pure Russian Roulette. I think Bhargava recently mentioned LNP bubble size as a potential payload randomizer. But VAERS is full of dilution/injection errors, including for the 5-11 product.
But the Röltgen, K. et al. paper suggests consistent payload at least in the sense that no one is getting “no spike.” 96% of recipients have detectable spike in plasma on day 1-2 and 63% at day 7. Similar results for mRNA and spike in the germ centers, with lots of hits still on day 37 post 2nd-dose and few after. So it seems like everyone who gets the shot is getting a lot of intact mRNA. The variability is in how long it sticks around.
Not discussed much, the paper also finds aberrantly cross-protective antibody enrichment against the RBD vs non-mRNA shots or infection with “Wuhan” strain (fig 4), as in binding against variants / binding against Wuhan ratio was much more even for Pfizer recipients. Even though the mRNA supposedly codes for the Wuhan spike. This suggests there is variability in the output, perhaps lots of mutant spike production, though it could also be some weird influence on APC epitope selection, maybe from the pseudouridine, maybe from the “slow release” factor of mRNA continuing to become available to APCs for weeks after dosage. Malone says the results suggest the mRNA is lingering in the immune cells but I think it reflects delayed capture from transfected non-immune cells.
Perhaps someone should have tested how these things work in a lab or something.
those LNP bubble sizes are extremely consistent
Interesting. I found my notes and it was Bhargava, but it was in a video so there were no citations. Superfluous anyway, if the mRNA payload is randomized or placebo'ed by other means.